Cost-effectiveness of atypical antipsychotics for the treatment of schizophrenia
J. bras. econ. saúde (Impr.); 8 (3), 2017
Objectives: To conduct a cost-effectiveness analysis of second-generation antipsychotics (SGA) for
schizophrenia in Brazil. Methods: A Markov model was built for the evaluation of the cost-effectiveness
of risperidone, quetiapine, ziprasidone and olanzapine in the Brazilian public health system. The time...
